Regeneron Pharmaceuticals, Inc.
REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including mā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$784.83
Price-0.93%
-$7.33
1Y
Price
Market Cap
$81.546b
Large
Price/Earnings 3y Avg5y Avg
18.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+30.6%
EBITDA Margin+21.7%
Net Profit Margin-
Free Cash Flow Margin+30.6%
EBITDA Margin+21.7%
Net Profit Margin-
Free Cash Flow MarginRevenue
$14.343b
+1.0%
1y CAGR+5.7%
3y CAGR-1.8%
5y CAGREarnings
$4.505b
+2.1%
1y CAGR+1.6%
3y CAGR-10.4%
5y CAGREPS
$41.48
+8.4%
1y CAGR+3.2%
3y CAGR-9.3%
5y CAGRBook Value
$31.257b
$40.559b
Assets$9.302b
Liabilities$2.706b
DebtDebt to Assets
6.7%
0.5x
Debt to EBITDAFree Cash Flow
$4.081b
-13.8%
1y CAGR-10.3%
3y CAGR-15.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company